Standpoint Research Downgrades Hologic (HOLX) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts HOLX Hot Sheet
Price: $76.01 --0%
Rating Summary:
6 Buy, 28 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 10 | New: 44
Rating Summary:
6 Buy, 28 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 10 | New: 44
Join SI Premium – FREE
Standpoint Research downgraded Hologic (NASDAQ: HOLX) from Buy to Hold.
For an analyst ratings summary and ratings history on Hologic click here. For more ratings news on Hologic click here.
Shares of Hologic closed at $25.80 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Argus Downgrades Alcoa (AA) to Hold
- JPMorgan Downgrades Ultrapar Holding (UGP) to Neutral
- CLSA Downgrades Samsung Biologics (207940:KS) to Hold (3)
Create E-mail Alert Related Categories
DowngradesRelated Entities
Standpoint ResearchSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
